6.86
price up icon104.78%   3.51
pre-market  プレマーケット:  6.86  
loading
前日終値:
$3.35
開ける:
$6.88
24時間の取引高:
24.71M
Relative Volume:
15.00
時価総額:
$552.48M
収益:
$414.29M
当期純損益:
$-99.81M
株価収益率:
-5.1393
EPS:
-1.3348
ネットキャッシュフロー:
$-28.65M
1週間 パフォーマンス:
+100.58%
1か月 パフォーマンス:
+89.50%
6か月 パフォーマンス:
+101.76%
1年 パフォーマンス:
-54.24%
1日の値動き範囲:
Value
$6.84
$6.92
1週間の範囲:
Value
$3.33
$6.92
52週間の値動き範囲:
Value
$3.08
$15.36

Accolade Inc Stock (ACCD) Company Profile

Name
名前
Accolade Inc
Name
セクター
Healthcare (1233)
Name
電話
610-834-2989
Name
住所
660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING
Name
職員
2,400
Name
Twitter
Name
次回の収益日
2025-01-09
Name
最新のSEC提出書
Name
ACCD's Discussions on Twitter

ACCD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Health Information Services icon
ACCD
Accolade Inc
6.86 552.48M 414.29M -99.81M -28.65M -1.3348
Health Information Services icon
VEEV
Veeva Systems Inc
217.30 35.28B 2.66B 665.91M 1.08B 4.05
Health Information Services icon
SOLV
Solventum Corp
68.96 11.91B 8.26B 66.00M 1.17B 0.3682
Health Information Services icon
DOCS
Doximity Inc
55.00 10.27B 516.85M 174.11M 217.38M 0.87
Health Information Services icon
HQY
Healthequity Inc
99.74 8.64B 1.15B 96.70M -161.99M 1.09
Health Information Services icon
WAY
Waystar Holding Corp
37.51 6.45B 906.14M -52.62M 89.62M -0.3621

Accolade Inc Stock (ACCD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-06-28 繰り返されました Needham Buy
2024-02-26 開始されました Leerink Partners Outperform
2024-01-17 再開されました DA Davidson Neutral
2024-01-03 開始されました Barclays Equal Weight
2023-05-24 アップグレード BofA Securities Neutral → Buy
2023-04-12 開始されました Stephens Overweight
2023-03-23 アップグレード Guggenheim Neutral → Buy
2023-02-09 ダウングレード Jefferies Buy → Hold
2023-02-02 開始されました Raymond James Outperform
2022-09-08 再開されました Piper Sandler Overweight
2022-09-07 開始されました Truist Buy
2022-08-12 開始されました DA Davidson Buy
2022-05-02 アップグレード Wells Fargo Underweight → Equal Weight
2022-04-29 ダウングレード BTIG Research Buy → Neutral
2022-04-29 ダウングレード BofA Securities Buy → Neutral
2022-04-29 ダウングレード Credit Suisse Outperform → Neutral
2022-04-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-04-29 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-04-11 開始されました Wells Fargo Underweight
2022-04-07 開始されました Guggenheim Neutral
2022-04-01 再開されました Credit Suisse Outperform
2022-02-11 開始されました Goldman Buy
2021-12-02 開始されました Jefferies Buy
2021-09-30 開始されました Berenberg Buy
2021-09-17 アップグレード Robert W. Baird Neutral → Outperform
2021-05-28 開始されました Robert W. Baird Neutral
2021-05-06 アップグレード SVB Leerink Mkt Perform → Outperform
2021-04-15 開始されました Needham Buy
2021-03-11 再開されました Goldman Buy
2021-01-15 アップグレード Credit Suisse Neutral → Outperform
2021-01-07 開始されました BTIG Research Buy
2020-12-08 開始されました Canaccord Genuity Buy
2020-09-22 開始されました DA Davidson Buy
2020-07-27 開始されました BofA Securities Buy
2020-07-27 開始されました Credit Suisse Neutral
2020-07-27 開始されました Goldman Buy
2020-07-27 開始されました Morgan Stanley Overweight
2020-07-27 開始されました Piper Sandler Overweight
2020-07-27 開始されました Robert W. Baird Outperform
2020-07-27 開始されました SVB Leerink Outperform
すべてを表示

Accolade Inc (ACCD) 最新ニュース

pulisher
07:09 AM

Accolade (NASDAQ:ACCD) Rating Lowered to Hold at Leerink Partnrs - MarketBeat

07:09 AM
pulisher
Jan 09, 2025

Transcarent to acquire health advocacy and primary care company Accolade for $621m - MSN

Jan 09, 2025
pulisher
Jan 09, 2025

Stifel Nicolaus Reaffirms Hold Rating for Accolade (NASDAQ:ACCD) - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Estimate suggests Accolade may outperform with a potential 320% upside - Dataconomy

Jan 09, 2025
pulisher
Jan 09, 2025

Accolade, with 500 employees in Montco, to be acquired in $621M deal - The Business Journals

Jan 09, 2025
pulisher
Jan 09, 2025

Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Raymond James - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Accolade to be acquired by Transcarent for $7.03 per share in cash - Yahoo Finance

Jan 09, 2025
pulisher
Jan 09, 2025

How Accolade stock pulled off a 105% jump - Dataconomy

Jan 09, 2025
pulisher
Jan 09, 2025

Stifel downgrades Accolade stock as competing bids deemed unlikely - Investing.com

Jan 09, 2025
pulisher
Jan 09, 2025

Stifel Downgrades Accolade Inc. (ACCD) to Hold - StreetInsider.com

Jan 09, 2025
pulisher
Jan 09, 2025

Raymond James Downgrades Accolade Inc. (ACCD) to Market Perform - StreetInsider.com

Jan 09, 2025
pulisher
Jan 09, 2025

Earnings Scheduled For January 9, 2025 - Benzinga

Jan 09, 2025
pulisher
Jan 08, 2025

Accolade Gets a Do-Over With Transcarent’s $621M Acquisition - MedCity News

Jan 08, 2025
pulisher
Jan 08, 2025

Seattle health care company to go private in $621 million acquisition deal - The Business Journals

Jan 08, 2025
pulisher
Jan 08, 2025

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc.ACCD - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Truist maintains Buy on Accolade stock, reiterates $7.50 target By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

What Transcarent's $621M Acquisition of Accolade Means for Behavioral Health - Behavioral Health Business

Jan 08, 2025
pulisher
Jan 08, 2025

Why Is Accolade Stock Trading Over 100% On Tuesday? - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

What's Going On With Accolade Stock Wednesday? - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Truist maintains Buy on Accolade stock, reiterates $7.50 target - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Leerink Partners - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade - Law360

Jan 08, 2025
pulisher
Jan 08, 2025

Geode Capital Management Increases Stake in Accolade, Inc. – Market - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Inc. (ACCD): Q3 2025 Earnings Preview and Stock Outlook – Market - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Halper Sadeh LLC Investigates Accolade, Inc. Sale to Transcarent for Fairness to Shareholders - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent to acquire fellow health benefits navigator Accolade for $621M - Healthcare Dive

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (ACCD) Stock Update: Analyst Ratings and Market Performance – Market - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Truist Securities Reiterates Buy Rating on Accolade Inc. (ACCD) - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Accolade, Inc.ACCD - Longview News-Journal

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (NASDAQ:ACCD) Shares Gap UpWhat's Next? - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade - GeekWire

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent to acquire Accolade for $621 million creating benefits tech giant - STAT

Jan 08, 2025
pulisher
Jan 08, 2025

ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Acquired by Transcarent in Strategic Merger - TipRanks

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade stock soars on $621M Transcarent acquisition deal - Investing.com

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent to acquire health benefits platform Accolade in $621M deal - Fierce healthcare

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (ACCD) to Resume Trading at 9 am - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent To Acquire Accolade - GlobeNewswire

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent To Acquire Accolade (ACCD) for $7.03 per share - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Exp - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Jan 08, 2025
pulisher
Jan 07, 2025

Transcarent, Inc. agreed to acquire Accolade, Inc. from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others. - Marketscreener.com

Jan 07, 2025
pulisher
Jan 06, 2025

Accolade’s chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Nigeria

Jan 06, 2025
pulisher
Jan 06, 2025

AcCOLADE EVP general counsel sells shares worth $1,338 - Investing.com India

Jan 06, 2025
pulisher
Jan 06, 2025

Accolade's chief accounting officer sells shares worth $1,785 - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

AcCOLADE EVP general counsel sells shares worth $1,338 By Investing.com - Investing.com Australia

Jan 06, 2025
pulisher
Jan 06, 2025

Accolade's chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Australia

Jan 06, 2025
pulisher
Dec 29, 2024

Newport News-based ivWatch receives accolades for life-saving technology - The Virginian-Pilot

Dec 29, 2024

Accolade Inc (ACCD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Accolade Inc (ACCD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
McHugh Colin
Chief Accounting Officer
Jan 03 '25
Sale
3.41
524
1,785
62,066
Cavanaugh Robert N
President
Jan 02 '25
Option Exercise
0.00
1,569
0
214,864
Cavanaugh Robert N
President
Jan 03 '25
Sale
3.41
553
1,884
214,311
SINGH RAJEEV
Chief Executive Officer
Jan 02 '25
Option Exercise
0.00
3,786
0
819,637
SINGH RAJEEV
Chief Executive Officer
Jan 03 '25
Sale
3.41
1,158
3,945
818,479
Barnes Stephen H.
Chief Financial Officer
Jan 02 '25
Option Exercise
0.00
1,569
0
222,032
Barnes Stephen H.
Chief Financial Officer
Jan 03 '25
Sale
3.41
535
1,823
221,497
Eskew Richard
EVP General Counsel
Jan 02 '25
Option Exercise
0.00
1,146
0
63,653
Eskew Richard
EVP General Counsel
Jan 03 '25
Sale
3.41
393
1,339
63,260
$21.16
price up icon 0.33%
$20.93
price up icon 3.10%
health_information_services WGS
$96.57
price down icon 0.48%
$17.32
price down icon 0.12%
health_information_services TEM
$37.49
price down icon 3.56%
health_information_services WAY
$37.51
price up icon 0.03%
大文字化:     |  ボリューム (24 時間):